Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept
W Luo, T Wen, X Qu - Journal of Experimental & Clinical Cancer Research, 2024 - Springer
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumors. The tumor
immune microenvironment (TIME) formed by interactions among cancer cells, immune cells …
immune microenvironment (TIME) formed by interactions among cancer cells, immune cells …
Prediction of tumor-reactive T cell receptors from scRNA-seq data for personalized T cell therapy
The identification of patient-derived, tumor-reactive T cell receptors (TCRs) as a basis for
personalized transgenic T cell therapies remains a time-and cost-intensive endeavor …
personalized transgenic T cell therapies remains a time-and cost-intensive endeavor …
Translational and oncologic significance of tertiary lymphoid structures in pancreatic adenocarcinoma
Z Gao, J Azar, H Zhu, S Williams-Perez… - Frontiers in …, 2024 - frontiersin.org
Pancreatic adenocarcinoma (PDAC) is an aggressive tumor with poor survival and limited
treatment options. PDAC resistance to immunotherapeutic strategies is multifactorial, but …
treatment options. PDAC resistance to immunotherapeutic strategies is multifactorial, but …
T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer
M Brennan, D DeBruin, C Nwokolo, KS Hunt… - Cancer Immunology …, 2024 - AACR
Emerging evidence in preclinical models demonstrates that antitumor immunity is not
equivalent between males and females. However, more investigation in patients and across …
equivalent between males and females. However, more investigation in patients and across …
Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms
R Pétremand, J Chiffelle, S Bobisse, MAS Perez… - Nature …, 2024 - nature.com
A central challenge in developing personalized cancer cell immunotherapy is the
identification of tumor-reactive T cell receptors (TCRs). By exploiting the distinct …
identification of tumor-reactive T cell receptors (TCRs). By exploiting the distinct …
An EBV-related CD4 TCR immunotherapy inhibits tumor growth in an HLA-DP5+ nasopharyngeal cancer mouse model
C Wang, J Chen, J Li, Z Xu, L Huang… - The Journal of …, 2024 - Am Soc Clin Investig
Adoptive transfer of T cell receptor–engineered T cells (TCR-T) is a promising strategy for
immunotherapy against solid tumors. However, the potential of CD4+ T cells in mediating …
immunotherapy against solid tumors. However, the potential of CD4+ T cells in mediating …
[HTML][HTML] CD39hi identifies an exhausted tumor-reactive CD8+ T cell population associated with tumor progression in human gastric cancer
Y Shen, Y Qiu, Z Duan, Y Li, Y Wang, Y Zhang… - Pharmacological …, 2024 - Elsevier
The ectonucleotidase CD39 has been regarded as a promising immune checkpoint in solid
tumors. However, the expression of CD39 by tumor-infiltrating CD8+ T cells as well as their …
tumors. However, the expression of CD39 by tumor-infiltrating CD8+ T cells as well as their …
[HTML][HTML] Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer
Y Chen, D Wang, Y Li, L Qi, W Si, Y Bo, X Chen, Z Ye… - Cancer Cell, 2024 - cell.com
Expanding the efficacy of immune checkpoint blockade (ICB) in colorectal cancer (CRC)
presses for a comprehensive understanding of treatment responsiveness. Here, we analyze …
presses for a comprehensive understanding of treatment responsiveness. Here, we analyze …
Machine learning for the identification of neoantigen-reactive CD8+ T cells in gastrointestinal cancer using single-cell sequencing
H Sun, X Han, Z Du, G Chen, T Guo, F Xie… - British Journal of …, 2024 - nature.com
Background It appears that tumour-infiltrating neoantigen-reactive CD8+ T (Neo T) cells are
the primary driver of immune responses to gastrointestinal cancer in patients. However, the …
the primary driver of immune responses to gastrointestinal cancer in patients. However, the …
Preoperative single-dose camrelizumab and/or microwave ablation in women with early-stage breast cancer: A window-of-opportunity trial
H Pan, M Yu, X Tang, X Mao, M Liu, K Zhang, C Qian… - Med, 2024 - cell.com
Background Immune checkpoint blockade has shown low response rates for advanced
breast cancer, and combination strategies are needed. Microwave ablation (MWA) may be a …
breast cancer, and combination strategies are needed. Microwave ablation (MWA) may be a …